EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections

Selwyn J Hurwitz, Ramyani De, Julia C LeCher iD, Jessica A Downs-Bowen iD, Shu Ling Goh iD, Keivan Zandi, Tamara McBrayer, Franck Amblard, Dharmeshkumar Patel iD, James J Kohler, Manoj Bhasin, Brian S Dobosh und 3 weitere

Viruses · 2024

DOI: 10.3390/v16040651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Selwyn J Hurwitz und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's…. Hauptthemen laut MEDLINE: Antiviral Agents, Drug Repositioning, SARS-CoV-2, COVID-19 Drug Treatment. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 208 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIMH NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most repurposed drugs have proved ineffective for treating COVID-19. We evaluated median effective and toxic concentrations (EC50, CC50) of 49 drugs, mostly from previous clinical trials, in Vero cells. Ratios of reported unbound peak plasma concentrations, (Cmax)/EC50, were used to predict the potential in vivo efficacy. The 20 drugs with the highest ratios were retested in human Calu-3 and Caco-2 cells, and their CC50 was determined in an expanded panel of cell lines. Many of the 20 drugs with the highest ratios were inactive in human Calu-3 and Caco-2 cells. Antivirals effective in controlled clinical trials had unbound Cmax/EC50 ≥ 6.8 in Calu-3 or Caco-2 cells. EC50 of nucleoside analogs were cell dependent. This approach and earlier availability of more relevant cultures could have reduced the number of unwarranted clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDrug RepositioningSARS-CoV-2COVID-19 Drug TreatmentHumansChlorocebus aethiopsVero CellsCaco-2 CellsAnimalsCOVID-19

Stichwörter der Autor:innen

COVID-19SARS-CoV-2antiviral agentscoronavirusdrug repurposingpharmacokineticspotencypotential efficacy

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, 1760 Haygood Drive, Atlanta, GA 30322, USA.
  • Center for Cystic Fibrosis & Airways Disease Research, Division of Pulmonary, Allergy & Immunology, Cystic Fibrosis and Sleep, Emory University and Children's Healthcare of Atlanta, 2015 Uppergate Drive, Atlanta, GA 303…
  • Morningside Center for Innovative and Affordable Medicine, Departments of Medicine and Hematology and Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.

ORCID-Profile: Julia C LeCher, Jessica A Downs-Bowen, Shu Ling Goh, Dharmeshkumar Patel, Rabindra M Tirouvanziam, Raymond F Schinazi

Förderung

  • NIAID NIH HHS
  • NIMH NIH HHS
  • NIH
  • Woodruff Health Sciences 2020 COVID-19 CURE award
  • Imagine, Innovate, and Impact (I3) Team Award Emory University School of Medicine
  • Center for AIDS Research

Zitieren

APA

Hurwitz, S. J., De, R., LeCher, J. C., Downs-Bowen, J. A., Goh, S. L., Zandi, K., McBrayer, T., Amblard, F., Patel, D., Kohler, J. J., Bhasin, M., Dobosh, B. S., Sukhatme, V., Tirouvanziam, R. M., & Schinazi, R. F. (2024). Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections. Viruses. https://doi.org/10.3390/v16040651

Vancouver

Hurwitz SJ, De R, LeCher JC, Downs-Bowen JA, Goh SL, Zandi K, et al. Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections. Viruses. 2024. doi:10.3390/v16040651

BibTeX
@article{Hurwitz2024,
  author = {Hurwitz, Selwyn J and De, Ramyani and LeCher, Julia C and Downs-Bowen, Jessica A and Goh, Shu Ling and Zandi, Keivan and McBrayer, Tamara and Amblard, Franck and Patel, Dharmeshkumar and Kohler, James J and Bhasin, Manoj and Dobosh, Brian S and Sukhatme, Vikas and Tirouvanziam, Rabindra M and Schinazi, Raymond F},
  title = {Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16040651}
}
Kostenlos starten →